Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 157.60M P/E - EPS this Y 10.80% Ern Qtrly Grth -
Income -49.97M Forward P/E -2.70 EPS next Y - 50D Avg Chg -8.00%
Sales 7.02M PEG - EPS past 5Y - 200D Avg Chg 5.00%
Dividend N/A Price/Book 2.86 EPS next 5Y - 52W High Chg -29.00%
Recommedations 1.40 Quick Ratio 2.35 Shares Outstanding 48.64M 52W Low Chg 67.00%
Insider Own 0.68% ROA -47.26% Shares Float 45.38M Beta 1.97
Inst Own 34.00% ROE -117.50% Shares Shorted/Prior 4.96M/4.20M Price 3.65
Gross Margin - Profit Margin - Avg. Volume 465,509 Target Price 9.40
Oper. Margin -737.80% Earnings Date Aug 7 Volume 408,001 Change -3.44%
About Cue Biopharma, Inc.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Cue Biopharma, Inc. News
05/11/24 Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
05/09/24 Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
05/08/24 Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
05/07/24 Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
04/25/24 Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
04/24/24 Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04/15/24 Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
04/09/24 Q4 2023 Cue Biopharma Inc Earnings Call
04/09/24 Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...
04/08/24 Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
04/02/24 Cue Biopharma to Host Business Update Call and Webcast
03/27/24 Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
02/29/24 Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
02/27/24 Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
02/06/24 Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:09 AM Cue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years ago
12/07/23 Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
11/22/23 Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
11/12/23 Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript
11/09/23 Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
CUE Chatroom

User Image Holmun Posted - 1 day ago

$CUE can any board member here comment on the validity of this statement? What are you guess as to the timing and size of an acquisition here?

User Image spylock Posted - 2 days ago

$CUE New to me. https://www.cuebiopharma.com/clinical-trials/expanded-access-policy/

User Image Holmun Posted - 3 days ago

$CUE @spylock Can you comment on the current state of CUE?

User Image Mastersushie1 Posted - 6 days ago

$CUE $holmun Dan'steadfast refusal to sell out completely prompts speculation: pride or foresight? 🤔 Some fear his biotech's confidence, driven by dreams of a Nobel Prize for the scientists, may lead to more debt, diluted investors, or even privatization. 8 years since the private placement, yet where's the shareholder value? Investor patience wanes as Dan's biotech spins its wheels, believing they can outsmart the market. Perhaps only Dan's retirement age appraching oddly coinciding with phase II trials' end in 24 monthw holds hope for a full sale. Meanwhile, they pursue partnerships, aiming to replicate their ONO success. Brace for prolonged single digit volatily and lets hope that they announce the partnership soon, they said 1H 2024, but management is incompetent and they have no sense of urgency. A fact is they only have cash until 1Q 2025, thus that partnership news must be on its way.

User Image Holmun Posted - 6 days ago

$CUE @Mastersushie1 Dr. Chu, could you please comment on CUE, and next steps.

User Image Mastersushie1 Posted - 6 days ago

$CUE Wow, what a fantastic display of incompetence by Cue Biopharma's management! Dropping 15% in a day takes real skill. Clearly, their management's motto is 'downward spiral or bust'.

User Image Bio_Be_Dirty Posted - 6 days ago

$CUE pump before offering in the couple months?

User Image JasoneBorneo1 Posted - 1 week ago

$CUE they need financing to start the trial. They only have nine months of money left give or take. starting trials not like going for a walk. You take a few steps yourself. It's a major commitment with personnel and facilities and recruiting sites. I personally think they have offers on the table, they could be waiting for ASCO data or add a few stock options to their name or both

User Image Invest2live Posted - 1 week ago

$CUE 20% already 😊🎈🎉🎊; congratulations

User Image epsguid Posted - 1 week ago

$CUE reported a loss of $0.25, consensus was ($0.30) via @eWhispers #epsbeat http://eps.sh/d/cue

User Image Stock_Titan Posted - 1 week ago

$CUE Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights https://www.stocktitan.net/news/CUE/cue-biopharma-reports-first-quarter-2024-financial-results-and-860agti8sjdt.html

User Image Holmun Posted - 1 week ago

$CUE @Mastersushie1 Dr. Chu, what are your thoughts on CUE lately? Are we close to an acquisition that will send the stock sky high?

User Image stedwi Posted - 1 week ago

$CUE Why the sell-off?

User Image Holmun Posted - 1 week ago

$CUE I can't believe the start of Phase 2 has yet to be announced. Does anyone else find this strange? Glass half full tells me that it's likely because the FDA is allowing them to proceed to Phase 3 straight away or that a partnership is being finalized, and that is the reason for the silence. Glass half empty tells me its the same lazy management that took two and a half years to wrap up Phase 1 and showed zero enthusiasm about getting this across the finish line. What do you all think?

User Image steven1x Posted - 1 week ago

$CUE if new https://viavid.webcasts.com/viewer/event.jsp?ei=1663846&tp_key=a8d4c834fe

User Image mlucasm Posted - 1 week ago

$CUE Not selling below $3

User Image Holmun Posted - 1 week ago

$CUE all things considered, I love the action lately..

User Image Invest2live Posted - 1 week ago

$CUE 29% congratulations 🎉🎈🎊; follow for more research based stock alerts

User Image Invest2live Posted - 1 week ago

$CUE congrats 🎈🎊🎉

User Image Holmun Posted - 1 week ago

$CUE with this kind of volume on super green days occurring more than once in a week has GOT to mean something. I know I possess undeniable wishful thinking here, but surely this is an objectively bullish sign that some kind of partnership ink is drying. Yes? No? Otherwise?

User Image Holmun Posted - 1 week ago

$CUE woah

User Image Holmun Posted - 2 weeks ago

$CUE Just voted AGAINST executive compensation packages.

User Image Holmun Posted - 2 weeks ago

$CUE it was certainly fun while it lasted.

User Image Fullratio Posted - 2 weeks ago

$CUE total assets is 152% greater than its total liabilities: https://fullratio.com/stocks/nasdaq-cue/cue-biopharma

User Image Stocksrunner Posted - 04/30/24

🚀 Today's Winners: Start Low, Finish High! 📈 $CGC kicked off at 8.20 but skyrocketed to 14.88, a whopping 81.46% surge! $CUE started at 1.40 and surged to 1.90, marking a remarkable 35.71% increase! $FLGC began at 1.26 and climbed to 1.69, boasting a fantastic 34.13% jump! $GRWG opened at 2.27 but surged to 2.99, achieving an impressive 31.72% rise! $LEXX commenced at 2.44 and surged to 3.09, a remarkable 26.64% leap! Incredible performance from these stocks! 🚀🔥

User Image debbiekatz Posted - 04/30/24

$cue 1.58 to 1.93 for 22% on the daytrade for team today. not bad.

User Image BChance Posted - 04/30/24

$CUE Maybe we'll just keep climbing back up to $3.00... That would be okay with me!

User Image JPecton Posted - 04/30/24

$CUE I like this set up

User Image BChance Posted - 04/30/24

$CUE Volume is very nice. This is looking very strong at the moment. Haven't seen this in quite sometime!

User Image Holmun Posted - 04/30/24

$CUE volume is through the roof! Someone knows something type of vibe. A massive purchase was made

Analyst Ratings
Stifel Buy Apr 9, 24
Oppenheimer Outperform Apr 9, 24
Piper Sandler Overweight Apr 3, 24
Jefferies Buy Mar 13, 24
Piper Sandler Overweight Nov 6, 23
Stifel Buy Jun 15, 23
JMP Securities Outperform May 15, 23
Stifel Buy Mar 22, 23
Oppenheimer Outperform Mar 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PASSERI DANIEL R CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 14 Buy 2.86 3,000 8,580 134,578 08/16/23
Fletcher Aaron G.L. Director Director May 23 Buy 3.43 205,000 703,150 940,000 05/25/22
Fletcher Aaron G.L. Director Director Mar 31 Buy 4.76 735,000 3,498,600 735,000 04/04/22
Pienta Kenneth Chief Medical Office.. Chief Medical Officer Feb 18 Option 3.57 20,274 72,378 6,274 02/18/21
Pienta Kenneth Chief Medical Office.. Chief Medical Officer Feb 18 Sell 15.1 20,274 306,137 2,000 02/18/21
Gray Cameron Director Director Oct 01 Buy 15.15 10,000 151,500 677,500 10/01/20